Shopping Cart 0
Cart Subtotal
USD 0

Intarcia Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Summary

Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc, is a biopharmaceutical company that focuses on the development of therapies through its proprietary Medici Drug Delivery System, a subcutaneous delivery system to treat chronic conditions. The company's product candidate includes ITCA 650, intended for the treatment of type II diabetes. It also carries out pipeline products in various therapeutic areas, including autoimmune diseases, obesity, HIV and other serious disorders. The company has manufacturing facility in Hayward, California; and research and development facility in Durham, North Carolina. Intarcia is headquartered in Boston, Massachusetts, the US.

Intarcia Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Intarcia Therapeutics Raises USD75 Million in Financing 12

Phoundry Pharma Raises USD0.5 Million in Seed Financing 13

Intarcia Therapeutics Raises USD 200 Million In Venture Financing 14

Intarcia Therapeutics Raises USD 210 Million In Venture Financing 16

Intarcia Therapeutics Raises USD0.7 Million in Venture Financing 18

Intarcia Therapeutics Raises Additional USD 5.5 Million In Venture financing 19

Intarcia Therapeutics Raises USD 7.3 Million In Venture financing 20

Partnerships 22

Intarcia Therapeutics Enters into Co-Development Agreement with Numab 22

Licensing Agreements 23

Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 23

Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 24

Intarcia Therapeutics Plans To License Drug-Formulation Technology 25

Equity Offering 26

Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 26

Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 27

Debt Offering 28

Intarcia Therapeutics Raises USD300 Million in Financing 28

Acquisition 29

Intarcia Therapeutics Acquires Phoundry Pharma 29

Intarcia Therapeutics Inc-Key Competitors 30

Intarcia Therapeutics Inc-Key Employees 31

Intarcia Therapeutics Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Product News 33

09/15/2017: New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes 33

Product Approvals 34

Feb 03, 2017: Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intarcia Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Intarcia Therapeutics Raises USD75 Million in Financing 12

Phoundry Pharma Raises USD0.5 Million in Seed Financing 13

Intarcia Therapeutics Raises USD 200 Million In Venture Financing 14

Intarcia Therapeutics Raises USD 210 Million In Venture Financing 16

Intarcia Therapeutics Raises USD0.7 Million in Venture Financing 18

Intarcia Therapeutics Raises Additional USD 5.5 Million In Venture financing 19

Intarcia Therapeutics Raises USD 7.3 Million In Venture financing 20

Intarcia Therapeutics Enters into Co-Development Agreement with Numab 22

Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 23

Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 24

Intarcia Therapeutics Plans To License Drug-Formulation Technology 25

Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 26

Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 27

Intarcia Therapeutics Raises USD300 Million in Financing 28

Intarcia Therapeutics Acquires Phoundry Pharma 29

Intarcia Therapeutics Inc, Key Competitors 30

Intarcia Therapeutics Inc, Key Employees 31

Intarcia Therapeutics Inc, Other Locations 32

Intarcia Therapeutics Inc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com